The short answer
Ozempic and Mounjaro are FDA-approved for type 2 diabetes; Wegovy and Zepbound are the weight-management brands of the same molecules and are not diabetes-indicated.
Wegovy specifically
Wegovy is the obesity brand of semaglutide — not indicated for diabetes. Use Ozempic for the diabetes indication.
BMI & eligibility
For type 2 diabetes there is no BMI requirement — the diagnosis itself (A1c ≥6.5%) supports coverage of Ozempic or Mounjaro.
Check your BMI
BMI calculator
BMI 27-29.9 — eligible if comorbidity (T2D, hypertension, sleep apnea, PCOS).
BMI is one signal among several. Waist circumference, body composition, metabolic markers, and clinical history also matter — talk to a prescriber.
Insurance & coverage
Type 2 diabetes is the easiest GLP-1 indication to get covered — most commercial and Medicare Part D plans cover Ozempic or Mounjaro on formulary, often with step therapy after metformin.
Check if your plan covers itWe earn affiliate commissions from listed providers. See our editorial standards.
Other GLP-1s for type 2 diabetes
Wegovy for other conditions
Sources
Educational information, not medical advice. FDA-approval status reflects labeling as of 2026; off-label prescribing is legal and common but coverage varies.